Mechanism of NFT formation
Mechanism of NFT formation
批准号:
13210147
负责人:
TAKASHIMA Akihiko
金额:
$38.4万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We generated the mouse overexpressing human 4 repeat tau driven by PDGF-β promoter, which contains V337M frontotemporal dementia-17(FTDP-17) mutation. The amount of expression was about 5-10% of endogenous mouse tau, and the accumulation of hyper-phosphorylated tau was seen in the hippocampus CA2 and 3 region and the cerebral cortex at 11 month old. At this age tau in Tg mouse became insoluble for SDS and form filamentous structure, and Tg mouse could form NFT with aging. The decrease in the neuronal activity in the hippocampus was observed in the electrophysiological experiments. In addition, Tg mice didn't show habituation, and significantly stay longer in open arm in elevated plus maze test. Thus, it was clarified that NFT formation reduced neural activity in hippocampus and caused behavioral disorder.In case of the other tau Tg mouse overexpressed human 4 repeat tau with the R406W mutation under control of CAMK II promoter, the mouse model also showed NFT like pathology accompanying with memory deficit, which pathophysiological features are very similar to the patient of AD and R406W. In addition, we could find the activation of GSK-3b and JNK in neurons, which accumulate hyperphosphorylated tau, suggesting that GSK-3 and JNK might be involved in NFT formation.To confirm the involvement of GSK-3 and JNK on NFT formation, we expressed JNK, deltaMEKK, GSK-3b, and human tau in COS7 cells. Tau showed the increased phosphorylation at 12 phosphorylation sites, including AT100 immunoreactive site, which is known as a peculiar antigen of PHF-tau seen in AD. SDS insoluble materials showed anti-phospho-tau immunoreactive aggregates. Thus, an excessive phosphorylation of Tau by GSK-3 β and JNK took part in NFT formation. In addition, when GSK-3 was activated by β amyloid, tau TG mouse resulted in the neurofibrillary tangle formation, the synapse loss, and the neuron death.
期刊论文(138)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.bbrc.2003.09.012
发表时间:
2003-10-17
期刊:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:
3.1
作者:
[Kimura, N, Tanemura, K, Yoshikawa, Y]
通讯作者:
Yoshikawa, Y
Kwok J.B., et al.: "Presenilin-1 mutation (Leu271VAL) results in altered exon 8 splicing and Alzheimer's disease with non-coded plaques and NO neuritic dystrophy"Journal of Biological Chemistry. (in press).
Kwok J.B. 等人:“Presenilin-1 突变 (Leu271VAL) 导致外显子 8 剪接改变以及伴有非编码斑块和 NO 神经炎性营养不良的阿尔茨海默病”《生物化学杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Takashima A.: "Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro : implications for the prevention and therapeutics of Alzheimer's disease."Neurochem. 87. 172-181 (2003)
Takashima A.:“多酚在体外有效的抗淀粉样蛋白生成和原纤维不稳定作用:对阿尔茨海默病的预防和治疗的影响。”Neurochem。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Takashima A.: "Alzheimer's Disease and Related Disorders : Research Advances""Ana Aslan" International Academy of Aging. 736 (2003)
Takashima A.:“阿尔茨海默氏病和相关疾病:研究进展”“Ana Aslan”国际衰老学院。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yoshiike Y, et al.: "New insights on how metals disrupt amyloid β-aggregation and their effects on amyloid-β cytotoxicity"J.Biol.Chem.. 276(34). 32293-32299 (2001)
Yoshiike Y 等人:“关于金属如何破坏淀粉样蛋白 β 聚集及其对淀粉样蛋白 β 细胞毒性的影响的新见解”J.Biol.Chem.. 276(34) (2001)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 62 条
国内基金
海外基金
登录
查看更多内容
益生菌通过肠-脑轴调控PI3K/AKt/GSK-3β信号通路促进缺血性脑卒中神经功能修复的分子机制研究
-
批准号:2026JJ81949
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘超
-
依托单位:
Cdc42通过抑制GSK-3β激酶活性介导YAP/TAZ异常激活在骨关节炎滑膜纤维化中的作用机制研究
-
批准号:2026JJ81824
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:吴克
-
依托单位:
基于AKT/GSK-3信号通路探讨“调和营卫”法中药制剂对小儿功能性消化不良作用机制研究
-
批准号:JCZRLH202601544
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
Trim37蛋白通过调控PTEN/AKT/GSK-3β/β-catenin信号通路影响肝细胞癌增殖、转移、耐药的分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王清清
-
依托单位:
艾司氯胺酮通过激活GSK-3β/PGC-1α通路促进小胶质细胞M2极化及抑制铁死亡改善PND的临床及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:付丽丽
-
依托单位:
GSK-3β/FBX8介导的CST1泛素化降解减少膀胱癌吉西他滨耐药的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:陈海潮
-
依托单位:
共负载si-SRGN-顺铂纳米投递系统调控CD44/GSK-3β/β-catenin靶向治疗口腔鳞癌
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:戚晓峰
-
依托单位:
健脾清热活血法通过 miR-632 靶向GSK-3β调节巨噬细胞极化改善慢性萎缩性胃炎的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:庄昆海
-
依托单位:
Sorbitol调节GSK-3β活性诱导PCOS卵巢颗粒细胞凋亡的作用机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:王翊丞
-
依托单位:
基于 GSK-3β/BACE1/APP信号通路研究功能性消化
不良 ICC 凋亡和自噬的机制及中药干预
-
批准号:2024JJ5309
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:郭璇
-
依托单位: